Source: Annual Congress 2004 - A translational approach to mechanisms of lung disease
Disease area: Interstitial lung diseases



Rating:

Share or cite this content

Citations should be made in the following way:
S. N. Vasilev, G. O. Kaminskaya, B. A. Serebryannaya, I. E. Stepanyan Shmelev, E. I. (Moscow, Russia). Hemostasis disorders and their correction using disaggregates and low-molecular heparins in patients with idiopathic fibrosing alveolitis (IFA). Eur Respir J 2004; 24: Suppl. 48, 2038

Member's Comments

No comment yet.

Related content which might interest you: Treatment of patients with idiopathic fibrosing alveolitis (IFA) using disaggregates and low-molecular heparin Source: Eur Respir J 2006; 28: Suppl. 50, 308s Year: 2006 Hemostasis disorders and their correction using ticlopidine in patients with cryptogenic fibrosing alveolitis (CFA) Source: Eur Respir J 2003; 22: Suppl. 45, 84s Year: 2003 Hemocoagulation and platelet aggregation disorders in patients with cryptogenic fibrosing alveolitis (CFA) Source: Eur Respir J 2002; 20: Suppl. 38, 226s Year: 2002 Clinical significance of morphological indexes of inflammation and sclerosis in idiopathic fibrosing alveolitis (IFA) and lung sarcoidosis Source: Eur Respir J 2002; 20: Suppl. 38, 107s Year: 2002 The study of C5a complement component in patients with idiopathic pulmonary fibrosis, toxic fibrosing alveolitis and extrinsic allergic alveolitis Source: Eur Respir J 2001; 18: Suppl. 33, 108s Year: 2001 Plasma fibronectin as the criterion of idiopathic fibrosing alveolitis severity Source: International Congress 2017 – IPF: from the bench to the bedside Year: 2017 Cytokine regulation in idiopathic fibrosing alveolitis (IFA) and lung sarcoidosis: clinicomorphological study Source: Eur Respir J 2001; 18: Suppl. 33, 107s Year: 2001 Rituximab in the management of idiopathic inflammatory myopathies complicated by interstitial lung disease Source: International Congress 2017 – The spectrum of CTDs: from pathogenesis to treatment Year: 2017 Idiopathic fibrosing alveolitis (IFA) as a background for the lung cancer development Source: Eur Respir J 2002; 20: Suppl. 38, 479s Year: 2002 Broncho-obstructive syndrome in patients with granulomatous pulmonary diseases. Source: International Congress 2019 – Sarcoidosis: a multifaceted disease that is difficult to manage Year: 2019 Specific features of the course of cryptogenic fibrosing alveolitis in pregnancy Source: Eur Respir J 2001; 18: Suppl. 33, 150s Year: 2001 Histological evaluation of transbronchial lung biopsy (TBBL) material in patients with idiopathic fibrosing alveolitis (IFA) Source: Eur Respir J 2001; 18: Suppl. 33, 62s Year: 2001 Familial case of cryptogenic fibrosing alveolitis in two siblings Source: Eur Respir J 2001; 18: Suppl. 33, 219s Year: 2001 Histopathological findings of biopsies from patients with extrinsic allergic alveolitis (hipersensitivity pneumonia) in subacute or chronic phase Source: Annual Congress 2013 –Diffuse parenchymal lung disease III Year: 2013 The features of the course of cryptogenic fibrosing alveolitis in women Source: Eur Respir J 2002; 20: Suppl. 38, 59s Year: 2002 Angiogenesis and coagulation in the development of pulmonary hypertension in idiopathic interstitial pneumonias (IIP) Source: Eur Respir J 2005; 26: Suppl. 49, 540s Year: 2005 Idiopatic fibrosing alveolitis functional respiratory disorders in children Source: International Congress 2016 – Orphan diseases II Year: 2016 Incidence and prevalence of idiopathic pulmonary fibrosis: review of the literature Source: Eur Respir Rev 2012 21: 355-361 Year: 2012 MMPs in BAL from patients with scleroderma fibrosing alveolitis Source: Eur Respir J 2006; 28: Suppl. 50, 564s Year: 2006 Different forms of allergic broncopulmonary aspergillosis(ABPA) in two cases; ABPA-serologic and ABPA-central bronchiectasis Source: Eur Respir J 2003; 22: Suppl. 45, 228s Year: 2003